Inoculation of a portion of marrow for transplant as a way to accelerate marrow recovery
In a recent issue of Bone Marrow Transplantation, Dr Häg-glund and his colleagues 1 reported on the intraosseous injection of marrow compared to intravenous infusion. In their studies, 38 patients у18 years of age were randomized to intraosseous + intravenous route (n = 10), intraosseous route alone (n = 8) or intravenous route alone (n = 20). Among their patients they found no significant differences in patient characteristics. They also found no significant difference in neutrophil recovery among all three groups. There appeared to be a significant reduction in the number of days on total parenteral nutrition and a trend towards the reduction in the number of days on antibiotics in the intraosseous group compared to the intravenous group. Of interest, was that bacteremia did not appear to occur in the intraosseous group compared to the intravenous group although the result was not significant. All of the other parameters they measured appeared to be identical. The conclusion of their study was that an allogeneic marrow transplant could safely be performed by the intraosseous route although they could not demonstrate a significant improvement in hematopoietic recovery.
In 1987, a randomized study was initiated in children, looking at the inoculation of marrow directly into the posterior iliac crests. Previous work had indicated that labeled marrow cells injected by this route migrated to the surrounding marrow cavities and labeled cells could be found in other marrow cavities at a later point. 2 In our initial studies, marrow recovery seemed to be equal or more rapid following the inoculation of marrow directly into marrow space. There was even the suggestion that B lymphocyte recovery was faster based upon the more rapid appearance of isohemagglutinins in inoculated patients. With that information in mind, a randomized trial was begun to see if there would be any advantage or disadvantage to such an intraosseous injection of marrow and if there were any limitations to the study.
In this randomized study, conducted over a period of 4 years, 26 children were included. They included children with acute lymphoblastic leukemia at various stages following initial diagnosis and recurrence, children with juvenile or adult-form CML, children with severe aplastic anemia and children with Burkitt's lymphoma. Twenty-five patients received marrow from either a partially matched family member or from a closely matched unrelated donor. 3 One patient received marrow from a matching sibling. Children eligible for this study were randomized to receive all of the marrow intravenously, as is usually done, or received 25% of the marrow injected directly into the posterior iliac crests and the remaining 75% injected intravenously. This design is not too dissimilar from that of Dr Hägglund and colleagues since the first group of randomized patients received either 100% of the marrow intravenously or 50% intravenously and 50% via the intraosseous route.
We found no difference in the intraosseous vs the intravenous group in terms of age of the children, dose of marrow administered, days to reach a total peripheral white count of 1000 cells/mm 3 and days to reach a neutrophil count Ͼ500 cells/mm 3 . There was a trend towards fewer platelet transfusions required in the group given marrow via the intraosseous route and a trend towards fewer inpatient days for the initial hospitalization. When looking at the last day when a platelet or red cell transfusion was given to patients in each group, there was a trend towards an earlier cessation of transfusion of red cells or platelets in the group receiving a portion of the marrow via the intraosseous route.
On all of the parameters measured to assess immune recovery 4 in terms of immunophenotyping subgroup analyses as well as lymphocyte functional assays, no significant differences were found between the two groups. Those receiving a portion of the marrow via the intraosseous group were never worse than the intravenous group on any of the parameters analyzed.
Our study was completed before the era of hematopoietic cytokines and, as a result, none of our patients received any cytokines. In the study by Dr Hägglund and colleagues, most of the patients did not receive any hematopoietic cytokines. Thus, neither study can address whether the selective use of hematopoietic cytokines given systemically or locally with the intraosseous marrow inoculum, result in an acceleration of hematopoietic recovery.
A variety of methods are currently used to facilitate stem cell growth. [5] [6] [7] [8] [9] It is possible that a larger study, combining several of the currently utilized techniques, might help to demonstrate an advantage to the intraosseous route. Just as with Dr Hägglund's study, we were unable to demonstrate any adverse problem to giving marrow via the intraosseous route and, from a technical point of view, it was extremely easy to do.
